Syntara: Funding, Investors & Team (Sep 2026)
Syntara is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. We are targeting extracellular matrix dysfunction with our world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. Our experienced team of scientists is focusing on correcting extracellular matrix (ECM) dysfunction. The ECM is a crucial component of the cell microenvironment, both under normal as well as fibrotic and inflammatory-driven disease states. By developing effective inhibitors of the key enzymes involved, we can correct dysfunction within the ECM, leading to positive outcomes in a range of diseases with high unmet need, including haematological malignancies such as myelofibrosis and myelodysplastic syndrome, chronic fibrosis (including skin scarring, pulmonary fibrosis, chronic kidney disease, NASH and cardiac fibrosis) and neuroinflammation.
Syntara has raised $4.7M across 1 funding round on record, the most recent an undisclosed round of $4.7M announced in Apr 2026.
That round is in line with the $5.2M median round size for Data and Analytics companies tracked on FundedIQ over the last two years.
Syntara Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Syntara Funding Rounds
Syntara Founders and Leadership Team
No contact details are on record for this team yet.
Syntara Funding Compared to Other Data and Analytics Startups
Syntara's latest round of $4.7M is in line with the median round in Data and Analytics. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Syntara in Data and Analytics and Sydney
Companies Similar to Syntara
Ideally is an on-demand insights and innovation platform that enables clients to rapidly test concepts, ideas…
Dataro uses AI-driven technology to transform how charity fundraising works. Its machine learning algorithms…
At Neara, we're helping utilities future-proof their infrastructure. We create 3D network-wide models that…
FloodMapp is a world-first predictive flood mapping technology, available as a suite of B2B Saas products.
Askable offers a comprehensive research platform that facilitates access to certified researchers and…
Terria is a geospatial technology company that creates digital twins using spatial data for planning,…
In the year 2000, a group of computer scientists came together in Sydney, Australia with a single idea: How…
Marqo is a vector search platform equipped with the essential machine learning capabilities and…
Avarni is a comprehensive software for managing carbon emissions that helps organizations of any size easily…
CipherStash is at the forefront of data security and offers advanced queryable encryption technology to keep…
DDLoop is developing an advanced data platform essential for lawyers to conduct due diligence. The legal data…
Alooba provides data assessments to help companies efficiently evaluate and screen candidates.
Syntara Funding FAQs
What does Syntara do?
Syntara is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. We are targeting extracellular matrix dysfunction with our world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. Our experienced team of scientists is focusing on correcting extracellular matrix (ECM) dysfunction. The ECM is a crucial component of the cell microenvironment, both under normal as well as fibrotic and inflammatory-driven disease states. By developing effective inhibitors of the key enzymes involved, we can correct dysfunction within the ECM, leading to positive outcomes in a range of diseases with high unmet need, including haematological malignancies such as myelofibrosis and myelodysplastic syndrome, chronic fibrosis (including skin scarring, pulmonary fibrosis, chronic kidney disease, NASH and cardiac fibrosis) and neuroinflammation.
How much funding has Syntara raised?
Syntara has raised $4.7M across 1 round on record. The most recent is an undisclosed round of $4.7M announced in Apr 2026.
When did Syntara last raise funding?
Syntara's most recent funding round on record is an undisclosed round of $4.7M, announced in Apr 2026.
Who founded Syntara?
FundedIQ lists Nooshin Yazhari (Founder) at Syntara.
Where is Syntara headquartered?
Syntara is based in Sydney, New South Wales, Australia.
How many employees does Syntara have?
Syntara is in the 51-100 employee band.
How does Syntara's funding compare to other Data and Analytics startups?
Syntara's latest round of $4.7M is in line with the $5.2M median round size for Data and Analytics companies on FundedIQ across 1,842 tracked companies over the last two years.
About FundedIQ's Syntara Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Syntara is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.